‡a
Author's Comparison of Eylea® with Lucentis® as first-line therapy in patients with treatment-naïve neovascular age-related macular degeneration in real-life clinical practice: retrospective case-series analysis
‡a
comparisonofeyleawithlucentisas1linetherapyinpatientswithtreatmentnaiveneovascularagerelatedmaculardegenerationinreallifeclinicalpracticeretrospectivecaseseriesanalysis
‡A
Comparison of Eylea® with Lucentis® as first-line therapy in patients with treatment-naïve neovascular age-related macular degeneration in real-life clinical practice: retrospective case-series analysis
‡9
1
‡a
comparisonofoutcomesandcostsofranibizumabandaflibercepttreatmentinreallife
‡A
Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life
‡9
1